2019
A Recurrence Predictive Model for Thymic Tumors and Its Implication for Postoperative Management: a Chinese Alliance for Research in Thymomas Database Study
Liu H, Gu Z, Qiu B, Detterbeck FC, Roden AC, Ruffini E, Okumura M, Girard N, Xiang Y, Liu Y, Du Z, Hao Y, Fu J, Zhang P, Pang L, Chen K, Wang Y, Yu Z, Mao T, Fang W, Group A. A Recurrence Predictive Model for Thymic Tumors and Its Implication for Postoperative Management: a Chinese Alliance for Research in Thymomas Database Study. Journal Of Thoracic Oncology 2019, 15: 448-456. PMID: 31726106, DOI: 10.1016/j.jtho.2019.10.018.Peer-Reviewed Original ResearchConceptsHigh-risk patientsAdjuvant therapyPostoperative yearThymic carcinomaComplete resectionPostoperative managementNeuroendocrine tumorsBootstrap-corrected C-indexChinese AlliancePostoperative adjuvant therapyIndependent predictive factorsLow-risk patientsMultivariate Cox regressionOverall survival rateAppropriate postoperative managementThymic epithelial tumorsHigh-risk groupLow-risk groupIIIA tumorsLocoregional recurrenceDisease recurrenceB3 thymomaHistologic typeNomogram modelT stage
2017
The Significance of Upfront Knowledge of N2 Disease in Non‐small Cell Lung Cancer
Thomas DC, Arnold BN, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, Boffa DJ, Kim AW. The Significance of Upfront Knowledge of N2 Disease in Non‐small Cell Lung Cancer. World Journal Of Surgery 2017, 42: 161-171. PMID: 28799084, DOI: 10.1007/s00268-017-4165-6.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerUnsuspected N2 diseaseIII-N2 non-small cell lung cancerN2 diseaseCell lung cancerSurgical resectionAdjuvant chemotherapyAdjuvant therapyOverall survivalPathologic stageLung cancerMultivariate analysisCurative-intent surgical resectionStage IIIA NSCLCHigher comorbidity scoreNational Cancer DatabaseIndependent risk factorKaplan-Meier analysisCN2 diseaseIIIA NSCLCComorbidity scoreCancer DatabaseRisk factorsRetrospective analysisRadiation therapyScientific Advances in Thoracic Oncology 2016
Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. Journal Of Thoracic Oncology 2017, 12: 1183-1209. PMID: 28579481, DOI: 10.1016/j.jtho.2017.05.019.Peer-Reviewed Original ResearchConceptsLung cancer careLung cancer researchValue of careAdjuvant therapyThoracic cancerCancer careLung cancerThoracic oncologyCare provideEarly detectionKinase inhibitorsGenomic testingImmunotherapyTherapyCancerCancer researchCareMultiple areasMolecular diagnosticsAnnual updateConcise reviewNSCLCInternational AssociationSurgeryMesotheliomaComparison of surgical approach and extent of resection for Masaoka-Koga Stage I and II thymic tumours in Europe, North America and Asia: an International Thymic Malignancy Interest Group retrospective database analysis†
Fang W, Yao X, Antonicelli A, Gu Z, Detterbeck F, Vallières E, Aye RW, Farivar AS, Huang J, Shang Y, Louie BE. Comparison of surgical approach and extent of resection for Masaoka-Koga Stage I and II thymic tumours in Europe, North America and Asia: an International Thymic Malignancy Interest Group retrospective database analysis†. European Journal Of Cardio-Thoracic Surgery 2017, 52: 26-32. PMID: 28329118, PMCID: PMC6279116, DOI: 10.1093/ejcts/ezx042.Peer-Reviewed Original ResearchConceptsExtent of resectionThymic tumorsStage IAsian patientsSurgical approachOnly independent predictive factorMasaoka-Koga stage IMore stage IOutcomes of patientsPathological stage IIndependent predictive factorsIndependent risk factorOverall survival rateCumulative recurrence rateSmaller tumor sizeRetrospective database analysisNorth American patientsPartial thymectomyAdjuvant therapyParaneoplastic syndromeThymic carcinomaOverall survivalPerformance statusComplete resectionMyasthenia gravis
2016
Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery
Thomas DC, Arnold BN, Rosen JE, Salazar MC, Blasberg JD, Detterbeck FC, Boffa DJ, Kim AW. Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery. Lung Cancer 2016, 103: 75-81. PMID: 28024700, DOI: 10.1016/j.lungcan.2016.11.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCombined Modality TherapyDatabases, FactualFemaleGuidelines as TopicHumansLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOutcome Assessment, Health CarePneumonectomyPostoperative PeriodRadiotherapySmall Cell Lung CarcinomaSurvival AnalysisConceptsStage I small cell lung cancerClinical stage ISmall cell lung cancerCell lung cancerAdjuvant chemotherapySurgical resectionPathologic upstagingStage IRadiation therapyNodal diseaseLung cancerPositive lymph node involvementNational Cancer DatabaseOutcomes of patientsLymph node involvementProportion of patientsCurative intentNodal upstagingSCLC patientsUpstaged patientsAdjuvant therapyNode involvementIndependent predictorsInferior survivalT descriptorThymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group
Shepherd A, Riely G, Detterbeck F, Simone CB, Ahmad U, Huang J, Korst R, Rajan A, Rimner A. Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group. Journal Of Thoracic Oncology 2016, 12: 745-751. PMID: 27876674, PMCID: PMC5545114, DOI: 10.1016/j.jtho.2016.11.2219.Peer-Reviewed Original ResearchConceptsInternational Thymic Malignancy Interest GroupThymic carcinomaAreas of controversyResectable diseaseMultimodality therapyClinical practiceFirst-line chemotherapy regimenDefinitive surgical resectionRare epithelial malignancyManagement of patientsCurrent clinical practiceFit patientsAdjuvant therapyChemotherapy regimenSurgical resectionThymic malignanciesHistologic confirmationTreatment courseTreatment strategiesEpithelial malignanciesGreat vesselsMultidisciplinary discussionGroup physiciansWorking GroupCarcinomaRole of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall
Gao SJ, Corso CD, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall. Clinical Lung Cancer 2016, 18: 169-177.e4. PMID: 27890561, DOI: 10.1016/j.cllc.2016.08.005.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdjuvant chemotherapyAdjuvant chemoradiation therapyUnderwent surgeryChemoradiation therapyChest wall resectionRadiation therapyMargin statusTumor sizeLung cancerWall resectionNode-negative lung cancerNational Cancer Data BaseCox proportional hazards modelMargin-positive patientsChest wall invasionCell lung cancerLog-rank testStage IIB tumorsProportional hazards modelAdjuvant therapyAdjuvant treatmentOverall survivalMultivariable analysisIIB tumors
2015
Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database
Leuzzi G, Rocco G, Ruffini E, Sperduti I, Detterbeck F, Weder W, Venuta F, Van Raemdonck D, Thomas P, Facciolo F, Group E. Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database. Journal Of Thoracic And Cardiovascular Surgery 2015, 151: 47-57.e1. PMID: 26403869, DOI: 10.1016/j.jtcvs.2015.08.034.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAsiaChemotherapy, AdjuvantChi-Square DistributionChildDatabases, FactualDisease ProgressionDisease-Free SurvivalEuropeFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingNorth AmericaPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentRisk FactorsSocieties, MedicalThymectomyThymomaThymus NeoplasmsTime FactorsTreatment OutcomeTumor BurdenYoung AdultConceptsRelapse-free survivalAdvanced thymomaMultimodality therapyOverall survivalT classificationPropensity score-matched cohort studyMultivariate Cox proportional hazards modelPropensity score-matched analysisCox proportional hazards modelPathologic T classificationStage III thymomaThoracic Surgeons databaseSignificant survival advantageSpecific pathologic featuresStrong predictive factorProportional hazards modelInduction therapyAdjuvant therapyPT3 tumorsCohort studyIndependent predictorsPrognostic impactMultivariable analysisPathologic featuresPredictive factors
2014
Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database
Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, Brunelli A, Evangelista A, Venuta F, Khaled A, Arame A, Refai M, Casadio C, Carbognani P, Cerfolio R, Donati G, Foroulis C, Gebitekin C, de Antonio D, Kernstine K, Keshavjee S, Moser B, Lequaglie C, Liberman M, Lim E, Nicholson A, Lang-Lazdunski L, Mancuso M, Altorki N, Nosotti M, Novoa N, Brioude G, Oliaro A, Filosso P, Saita S, Scarci M, Schützner J, Terzi A, Toker A, Van Veer H, Anile M, Rendina E, Voltolini L, Zurek W. Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database. European Journal Of Cardio-Thoracic Surgery 2014, 46: 361-368. PMID: 24482389, PMCID: PMC4155438, DOI: 10.1093/ejcts/ezt649.Peer-Reviewed Original ResearchConceptsOverall survivalAdjuvant therapyIncomplete resectionComplete resectionThymic tumorsTumor sizeWorld Health Organization histologyTen-year OSDisease-free survivalEuropean SocietyType of resectionClinical pathological characteristicsRisk of recurrenceShorter overall survivalThoracic Surgeons databaseR0 resectionCohort studyCumulative incidenceSecondary outcomesImproved survivalPrimary outcomePrognostic factorsIncident casesPrognostic predictorSurgeons database
2013
Pediatric thymomas: report of two cases and comprehensive review of the literature
Fonseca AL, Ozgediz DE, Christison-Lagay ER, Detterbeck FC, Caty MG. Pediatric thymomas: report of two cases and comprehensive review of the literature. Pediatric Surgery International 2013, 30: 275-286. PMID: 24322668, DOI: 10.1007/s00383-013-3438-x.Peer-Reviewed Original ResearchConceptsStage diseaseSurgical excisionRare pediatric malignancyMasaoka stage IEarly-stage diseaseSlight male predominanceTreatment of thymomaLate-stage diseaseMulti-institutional studyPediatric thymomaAdjuvant therapyClinical courseMyasthenia gravisPrognostic factorsMale predominanceIndolent behaviorPediatric malignanciesRare tumorCase reportReference listsStage IIIThymomaStage IStage IVPubMed database
2008
What to do with “Surprise” N2?: Intraoperative Management of Patients with Non-small Cell Lung Cancer
Detterbeck F. What to do with “Surprise” N2?: Intraoperative Management of Patients with Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 289-302. PMID: 18317073, DOI: 10.1097/jto.0b013e3181630ebd.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerMediastinal lymph node dissectionLymph node dissectionMediastinal lymph nodesPositive prognostic factorCell lung cancerAdjuvant therapyNode dissectionLung resectionLymph nodesMalignant involvementPrognostic factorsIntraoperative managementLung cancerPatientsConflicting dataResectionTherapyCancerDiseaseDissectionComprehensive reviewThe Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer
Stinchcombe TE, Harper HD, Hensing TA, Moore DT, Crane JM, Atkins JN, Willard EM, Detterbeck FC, Socinski MA. The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 145-151. PMID: 18303435, DOI: 10.1097/jto.0b013e318160c5f1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantDocetaxelDrug-Related Side Effects and Adverse ReactionsFeasibility StudiesFemaleHumansLung NeoplasmsMaleMiddle AgedPatient ComplianceSurvival AnalysisTaxoidsConceptsNon-small cell lung cancerCell lung cancerAdjuvant therapySupportive therapyChemotherapy complianceLung cancerAdequate exposureResected non-small cell lung cancerAdjuvant cisplatin-based chemotherapyMulticenter phase II trialMedian age 65 yearsCycles of therapyPrimary end pointAcceptable toxicity profileBetter functional statusPhase II trialCisplatin-based chemotherapyMajority of patientsSquamous cell carcinomaAge 65 yearsAdjuvant carboplatinCommon histologyII trialIntercurrent illnessActive therapy